The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b
Open accessAbstract
Purpose: Effective systemic therapy for advanced carcinoid is lacking. The combination of bevacizumab (BEV) and pegylated (PEG) interferon alfa-2b was evaluated among patients with metastatic or unresectable carcinoid tumors. Patients and Methods: Forty-four patients on stable doses of octreotide were randomly assigned to 18 weeks of treatment with bevacizumab or PEG interferon alfa-2b. At disease progression (PD) or at the end of 18 weeks (whichever occurred earlier), patients received bevacizumab plus PEG interferon until progression. Functional computer tomography (CT) scans were performed to measure effect on tumor blood flow. Results: In the bevacizumab arm, four patients (18%) achieved confirmed partial response (PR), 17 patients (77%) had stable disease (SD), and one patient (5%) had PD. In the PEG interferon arm, 15 patients (68%) had SD and six patients (27%) had PD. Progression-free survival (PFS) rates after 18 weeks of monotherapy were 95% in bevacizumab versus 68% on the PEG interferon arm. The overall median PFS for all 44 patients is 63 weeks. Compared with paired baseline measurements on functional CT scans, we observed a 49% (P < .01) and 28% (P < .01) decrease in tumor blood flow at day 2 and week 18 among patients treated with bevacizumab. No significant changes in tumor blood flow were observed following PEG interferon. PEG interferon alfa-2b treatment was associated with decrease in plasma basic fibroblast growth factor (bFGF; P = .04) and increase in plasma interleukin-18 (IL-18; P < .01). No significant changes in bFGF or IL-18 following treatment with bevacizumab were observed. Conclusion: Bevacizumab therapy resulted in objective responses, reduction of tumor blood flow, and longer PFS in patients with carcinoid than PEG interferon treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
Faiss, S., Pape, U.-F., Böhmig, M., Dörffel, Y., Mansmann, U., Golder, W., Riecken, E. O., & Wiedenmann, B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.142 · Cited by 501
Sun, W., Lipsitz, S., Catalano, P., Mailliard, J. A., & Haller, D. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.616 · Cited by 357
von Marschall, Z., Scholz, A., Cramer, T., Schafer, G., Schirner, M., Oberg, K., Wiedenmann, B., Hocker, M., & Rosewicz, S. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.437 · Cited by 328
Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1143 · Cited by 312
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
Terris, Scoazec, Rubbia, Bregeaud, Pepper, Ruszniewski, Belghiti, FLÉjou, & Degott (1998) · Histopathology · doi:10.1046/j.1365-2559.1998.00321.x · Cited by 279
Kölby, L., Persson, G., Franzén, S., & Ahrén, B. (2003) · British Journal of Surgery · doi:10.1002/bjs.4149 · Cited by 222
Janson, E. T., & Öberg, K. (1993) · Acta Oncologica · doi:10.3109/02841869309083916 · Cited by 204
Carcinoid A Comprehensive Review
Schnirer, I. I., Yao, J. C., & Ajani, J. A. (2003) · Acta Oncologica · doi:10.1080/02841860310010547 · Cited by 192
Self-citationFrank, M. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00146-x · Cited by 191
Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumours
Janson, E. T., Ahlström, H. K., Andersson, T., & Öberg, K. E. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90060-f · Cited by 130
Ambs, S., Bennett, W. P., Merriam, W. G., Ogunfusika, M. O., Oser, S. M., Khan, M. H., Jones, R., & Harris, C. C. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.470 · Cited by 124
Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium
Adams, R. L., Adams, I. P., Lindow, S. W., Zhong, W., & Atkin, S. L. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602503 · Cited by 122
Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells
Mentlein, R., Eichler, O., Forstreuter, F., & Held‐Feindt, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1223 · Cited by 100
Clinical and In vitro Studies of Imatinib in Advanced Carcinoid Tumors
Yao, J. C., Zhang, J. X., Rashid, A., Yeung, S. J., Szklaruk, J., Hess, K. R., Xie, K., Ellis, L. M., Abbruzzese, J. L., & Ajani, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1618 · Cited by 88
Self-citationReyno, L. M., Seymour, L., Tu, D., Dent, S. F., Gelmon, K. A., Walley, B. A., Pluzanska, A., Gorbunova, V. A., Garin, A., Jassem, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.075 · Cited by 62
Wang, J., Li, J., Zhai, Z.-M., Xue, Q., Jia, W., Xu, G., Xu, R.-N., Sun, H., Wang, L., & Yu, J.-H. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0447-5 · Cited by 54
Konno, H., Arai, T., Tanaka, T., Baba, M., Matsumoto, K., Kanai, T., Nakamura, S., Baba, S., Naito, Y., Sugimura, H., et al. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00651.x · Cited by 49
Cited by
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Zaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., Oberg, K., Pelosi, G., Perren, A., Rossi, R. E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv041 · Cited by 714
Metadata
- Authors
- Yao, J. C., Phan, A., Hoff, P. M., Chen, H. X., Charnsangavej, C., Yeung, S.-C. J., Hess, K., Ng, C., Abbruzzese, J. L., & Ajani, J. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-03-10
- Volume
- 26
- Issue
- 8
- Pages
- 1316-1323
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166100060
- Cited by
- 414
- References
- 19
- FWCI
- 25.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.